FDA
-
-
-
-
-
-
-
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
-
-
-
-
-
-
-
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
-
-
-
-
-
-
-
Cytokinetics to Participate in March Investor Conferences
-
-
-
-
-
-
-
Cytokinetics launches MYQORZO for hypertrophic cardiomyopathy in US
-
-
-
-
-
-
-
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Of
-
-
-
-
-
-
-
Here's the list of top biotech stocks to own for 2026
-
-
-
-
-
-
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

